J.P. Morgan 2024: Ipsen discusses progress, next phase of growth and partnering ambition

At the J.P. Morgan Healthcare Conference in San Francisco from January 8 to 11, 2024,  Ipsen’s management team leaders will discuss our transformation story, next phase of growth and external innovation ambitions.

Keeping up the growth momentum

Over the past three years, we have completely transformed our business and pipeline, delivering on the strategic roadmap established at the end of 2020. We are now ready for the next phase of our transformation.

In full-year 2022, Ipsen passed €3 billion in total sales.  Our portfolio includes four medicines – Dysport, Cabometyx, Decapeptyl as well as Somatuline – each set deliver sales of at least €500m. In the longer term, we anticipate seven medicines in our portfolio that could reach this potential, positioning us well to sustain attractive growth. 

Now, we are gearing for further growth in the period 2023-2027. In December 2023, Ipsen provided a midterm outlook at its Capital Markets Day – an average total-sales growth of at least 7% per year (at constant exchange rates) and a core operating margin in 2027 of at least 32% of total sales. This outlook excludes the impact of any late-stage external-innovation opportunities.

Presenting a strong investment case

CEO David Loew and CFO Aymeric Le Chatelier are attending the conference, alongside the Investor Relations and Business Development teams. On January 9, David Loew will deliver a presentation on Ipsen’s strategic progress, the mid-term outlook and growth opportunities. His talk will be followed by a Q&A session. We are also organizing a series of meetings to discuss our compelling investment case with investors and analysts. If you are an investor would like to meet our executives and Investor Relations team, we encourage you to contact JP Morgan to arrange a meeting.

Partnering for life-changing impact

At Ipsen, we know that great partnerships create great possibilities and bring therapeutic solutions to patients faster. In recent years, we acquired two global biotechs – Epizyme and Albireo – and signed deals that fuelled our pipeline with a further 20+ programs. Looking ahead, we are anticipating some exciting R&D milestones in the near-term. We are also accelerating our external innovation efforts to continue to boost our pipeline across all phases of development. Based on strong levels of free cash flow and profitability, our cumulative balance-sheet firepower for deal opportunities could reach up to €5bn by 2027.

Chief Business Officer Philippe Lopes-Fernandes, Head of R&D Christelle Huguet and the partnering team will attend the J.P. Morgan Healthcare Conference. They will be available in San Francisco to meet with potential partners working in Ipsen’s three therapeutic areas – Oncology, Rare Disease and Neuroscience – and discuss our track record of optimizing the impact of our partners’ programs.

Philippe will also participate to the panel “Removing Barriers: Healthcare Access and Equity for Al” at the Biotech Showcase on January 9.

We invite interested parties to contact us and arrange a meeting beforehand.

For more information on Ipsen, please visit our Investors and Partnering pages.